Dilek Çağlayan

6PUBLICATIONS
63CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 19, 2026
Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.

Dilek Çağlayan, Melek Çağlayan

|Jan 28, 2026
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.

Engin Hendem, Mehmet Zahid Koçak, Ayşegül Merç Çetinkaya

|Dec 19, 2025
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study.

Bilgeşah Kılıçtaş, Murat Araz, Ahmet Oruç

|Nov 10, 2025
Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab.

Esra Zeynelgil, Dilek Çağlayan, Selahattin Çelik

|Sep 24, 2024
The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients.

Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli

Pageof 1